Case Study: an Italian multinational pharmaceutical company achieves timely FDA CARES Act compliance with Freyr

Italian Multinational Pharma Company submits 2023 FDA CARES Act report on time with FREYR

An Italian multinational pharmaceutical company required assistance in preparing and submitting its 2023 FDA CARES Act Report to the US FDA. The client faced the challenges of compiling and verifying report content under strict deadlines while ensuring full compliance with this specialized obligation. They sought a structured solution to avoid delays and partnered with FREYR for regulatory execution support.

FREYR implemented a reporting-focused workflow that assessed requirements, compiled and reviewed the submission content, and structured the final package for the FDA. This support from FREYR enabled the timely submission of the report, strengthened the client's compliance processes, and reduced the execution burden on their internal teams. The engagement created a repeatable model for efficiently managing future reporting requirements.